Want to see TOVX full AI Analyst Report?
TOVX Stock Chart & Stats
$0.22
>-$0.01(-4.44%)
At close: 4:00 PM EDT
$0.22
>-$0.01(-4.44%)
Day’s Range― - ―
52-Week Range$0.16 - $0.86
Previous Close$0.22
Volume479.63K
Average Volume (3M)8.88M
Market Cap
$10.35M
Enterprise Value$3.70
Total Cash (Recent Filing)$11.34M
Total Debt (Recent Filing)$3.55M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 17, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding45,892,670
10 Day Avg. Volume25,882,304
30 Day Avg. Volume8,875,558
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.17
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.00Price Target Upside354.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.23
Revenue Forecast (FY)$29.37M
Bulls Say, Bears Say
Bulls Say
VIRAGE2 Clinical DevelopmentStarting VIRAGE2 advances VCN-01 into a focused clinical study and generates safety, pharmacodynamic and dosing data. Successful execution could refine the regimen for a pivotal Phase 3 program and improve the asset’s partnering or commercialization prospects.
Prior VCN-01 Efficacy SignalThe earlier survival benefit provides a clinically meaningful foundation for further development rather than relying only on laboratory evidence. EMA and FDA acknowledgement of the finding also supports continued regulatory engagement and increases the program’s strategic credibility.
Oncolytic Virotherapy PlatformEvidence of stromal degradation, viral activity and increased cytotoxic T-cell infiltration suggests a differentiated mechanism that may support combinations across solid tumors. A broader platform opportunity could increase the value of VCN-01 beyond a single pancreatic cancer indication.
Bears Say
Limited Commercial TractionTheriva has not demonstrated scalable commercial demand because it remains dependent on clinical development rather than marketed products. The very small revenue base leaves little operating leverage and means future value depends heavily on successful trials and eventual regulatory approval.
Persistent Cash ConsumptionOngoing negative cash flow indicates that research and clinical operations cannot currently fund themselves. Continued development will likely require additional capital, leaving the company exposed to financing availability and increasing the risk that programs are slowed or reprioritized.
Shrinking Equity And Dilution RiskCumulative losses are consuming the equity cushion, while expanded share authorization and incentive capacity increase potential dilution. If cash burn persists, financing may be needed before clinical milestones mature, reducing existing holders’ ownership and financial flexibility.
Theriva Biologics News
TOVX FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was $0.16 and its highest was $0.86 in the past 12 months.
What is Theriva Biologics’s market cap?
Theriva Biologics’s market cap is $10.35M.
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is Nov 17, 2026 which is in 89 days.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on Aug 11, 2026. The company reported -$0.07 earnings per share for the quarter, missing the consensus estimate of -$0.055 by -$0.015.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Undervalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -0.07.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 45,892,670 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of -$0.07 in its last earnings report, missing expectations of -$0.055. Following the earnings report the stock price went down -0.433%.
Which hedge fund is a major shareholder of Theriva Biologics?
Currently, no hedge funds are holding shares in TOVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Theriva Biologics
Theriva Biologics Inc. is a clinical-stage biotechnology firm dedicated to developing novel treatments for conditions with significant unmet medical needs. The company's pipeline features several promising candidates, including SYN-004, which is engineered to break down commonly used intravenous beta-lactam antibiotics in the gastrointestinal tract. This degradation aims to avert microbiome damage, Clostridioides difficile infection (CDI), the overgrowth of harmful organisms, the rise of antimicrobial resistance (AMR), and acute graft-versus-host disease (aGVHD) in patients undergoing allogeneic hematopoietic cell transplants. Another key investigational therapy is SYN-020, an orally administered recombinant formulation of intestinal alkaline phosphatase, designed to address both localized gastrointestinal and systemic diseases. Additionally, Theriva Biologics is advancing VCN-01 for the treatment of various cancers, specifically pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. Its broader clinical-stage portfolio includes SYN-006, intended to prevent aGVHD and infections caused by carbapenem-resistant enterococci; SYN-007, aimed at preventing antibiotic-associated diarrhea linked to oral beta-lactam antibiotics; SYN-005, for both the prevention and treatment of pertussis; and VCN-11, another cancer-focused therapy. The company collaborates with institutions such as Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. Furthermore, a clinical trial agreement with Washington University School of Medicine in St. Louis is in place to conduct a Phase 1b/2a clinical trial for SYN-004. Formerly known as Synthetic Biologics, Inc., the company rebranded as Theriva Biologics Inc. in October 2022 and is headquartered in Rockville, Maryland.
TOVX Stock 12 Month Forecast
Average Price Target
$1.00
▲(354.55% Upside)
Technical Analysis
Ownership Overview
0.57%
Insiders
0.90% Mutual Funds
0.35% Other Institutional Investors
97.12% Public Companies and
Individual Investors